News
Dealbreaker on MSN1h
Gilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition
Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...
MyChesCo on MSN8h
Kite to Buy Interius BioTherapeutics for $350 Million, Advancing In Vivo CAR T Strategy
Kite, a Gilead company (Nasdaq: GILD), has agreed to acquire Interius BioTherapeutics for $350 million in cash, a move aimed at bringing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback